The Food and Drug Safety and Innovation Action (FDASIA) grants the FDA authority to approve eligible treatments for life-threatening illnesses. On April
25
, we'll be urging the FDA to use that power to approve eteplirsen for the treatment of Duchenne muscular dystrophy. We're simply asking them to follow the evidence.